Our researchers study everything from the mechanisms underlying disease through to full-scale clinical trials. These projects have resulted in long-term partnerships with over 100 companies in the last ten years. These have ranged from start-ups and small businesses to global pharmaceutical companies.
A number of spin-out companies have been formed by research scientists from the School of Medicine.
Exonate is a biopharmaceutical company focused on the discovery and development of small molecule drugs. They're specifically interested in those which modulate alternative mRNA splicing to address diseases of high unmet medical need.
Visit Exonate website
FaHRAS is a sophisticated evidence-based software system that enables the user to build and store a family history. It also runs a variety of analyses against their family history to quantify their risk of developing breast cancer.
Visit FaHRAS website
NuVision was incorporated on 10 July 2014 and aims to develop and accelerate to market new regenerative therapies. Initially focused on treating eye disease and trauma, it's now expanding into the chronic wound arena.
Visit NuVision website
Oncimmune was set up in 2003 to commercialise a test to detect cancer.
Visit Oncimmune website
Platelet Solutions was formed in 2011 focusing on platelet function testing in any healthcare setting.
Visit Platelet Solutions website
Scancell’s mission is to develop products that stimulate the immune system to treat or prevent cancer.
Visit Scancell website
University of NottinghamMedical School Nottingham, NG7 2UH
Contacts: For admissions enquiries, call 0115 951 5559. For other enquiries, call 0115 823 0031 ext.30031 or please see our 'contact us' page for further details